American Chiropractors Directory and News

~ Approximately a two-fold increase in back pain cases in the 8-20 year old age group and a four-fold increase in the 25-50 year old adults ~

Pune: Like bone, muscle, and neck pain, lower back pain is a common occurrence in children and adults these days in these unprecedented times. Prolonged screen time, poor posture, physical inactivity, and irregular schedules have all caused back pain in children ages 8 to 20 and adults ages 25 to 50. It is important to stick to ergonomics, maintain good posture when sitting, avoid lifting heavy objects, and divide the household chores among the family to relieve lower back pain.

Shubham, 14, has suffered from back pain and mild fatigue for the past two months from online training. His pain persisted even after taking medication. Then he was recommended physiotherapy to correct his posture. Mild pain reliever for quick relief and cravings. For example, many patients work from home or even children use computers where posture is slightly compromised and the problem starts with chronic pain.

Dr. Vishwajit Chavan, Shoulder and Knee Arthroscopy and Joint Replacement Orthopedic Advisor, Apollo Spectra Pune, said, “Now, for over a year, children and adults have been at home taking their online training courses and working from home because of the pandemic strained her back. Even housewives have to do chores in the absence of housekeeping, and that, too, has made lower back pain worse. The main reason is that because of sitting in one position for long periods of time or working from home, people eat at shorter intervals but in large portions. Therefore, due to the completion of the work in a deadline, they do not move much. This increases stress, you eat unhealthily and back problems arise. “

Dr. Mayank Pathak, orthopedist and joint replacement surgeon at Apollo Clinic, Pune, emphasized: “Initially, many employees gave the home work policy a green signal. But the long shifts and online courses, the lifting of heavy objects, the poor posture when sitting, due to the unavailability of specially designed chairs for the back and adjustable monitors, many children and adults complain of lower back pain as they spend a long time in the Incorrect sitting posture that has led to pain in the spine. Binge-watching movies with a lack of sleep and rest at home can lead to stiffness and back pain. And even those with existing back problems have difficulties because their pain has increased. “

Dr. Pathak added: “The age group of patients between 8 and 20 years of age is roughly doubling and that of adults in the age group 25-50 who visit daily with complaints of back pain has increased four-fold in the base in the last 6 months during and after the second wave. ”

Dr. Chavan added, “Don’t just rest in bed for long hours, as the body can become stiff, get up, stand, and stretch to relieve lower back pain. Children and adults should opt for a cold compress to help relieve back pain. Avoid sugary, processed, and fried foods that can make pain worse, limit food intake from restaurants, and eat fresh fruits, vegetables, and whole grains. Include onion, berries, ginger, turmeric, and garlic in your diet to help manage back pain. ”

“The bed, couch, kitchen table, or couch has now become work tables, so make sure you have your own desk and chair for work and online classes. When sitting, maintain good posture, do not sit with a hunched back or in a hunched position, and take frequent breaks. Squats for lifting heavy objects and adults shouldn’t do rigorous exercises without a warm-up. The red flags of back pain include unintentional weight loss, impaired gait, fever, or weakness in nerves and limbs and should not be ignored. Use a good chair that supports your spine, ”concluded the Dr. Pathak Apollo Clinic.

Marrickville, NSW – Podiatry has been used for years to provide a variety of benefits for people with foot and ankle conditions to treat their chronic conditions. People with Achilles tendon tendinopathy, recurrent ankle pain, heel pain, bunions, fractures, and other causes of foot pain have relied on various podiatric treatments to manage their conditions. Movement 101 is one of the premier podiatrists in Marrickville, NSW with years of experience helping clients improve their health through reliable podiatry services.

Movement 101 is operated by fully certified podiatrists with the experience and resources to prevent or treat existing foot problems. They specialize in all types of lower limb pain and injuries such as plantar fasciitis and other causes of heel pain or arch pain, forefoot injuries such as metatarsalgia, sesamoiditis, and other causes of forefoot pain. The team also deals with injuries to lawn toe and plantar plates, shin splints and leg pain, Achilles tendinopathy, peroneal tendinopathy and sinus tarsi syndrome, recurrent ankle sprains, chronic knee pain (e.g. jumper’s knee, runner’s knee such as corns), skin injuries and calluses on the feet, blisters, damaged or ingrown toenails, etc.

Movement 101 specialists use cutting edge technology and a range of advanced podiatry treatments and products such as orthotics, shock wave therapy, sports injury treatment, diabetic foot treatment, biomedical exams, 3D foot scans and orthotics, skin, bladder and nail care, etc. your podiatry Techniques and products are designed to produce significant results from the first appointment by helping clients relieve pain, improve movement, speed recovery, and build fitness and strength.

Regarding their podiatry services and how the center combines them with other treatments, the company’s representative says, “Movement 101 uses a number of advanced podiatry techniques to produce results that clients can feel from their first appointment. They are designed to improve patient wellbeing. In addition, depending on individual patient needs, the center often combines total podiatry care services with physiology, Pilates or exercise physiology programs in order to achieve the best possible results. “

In addition to first-class podiatry services, Movement 101 specializes in physiotherapy to treat various neuromuscular conditions such as back, spine or neck pain, spinal disc injuries, lack of exercise or strength, chronic pain, traumatic injuries, persistent headaches, recovery treatments, work injuries, whiplash and others Vehicle injuries, etc.

While Movement 101 isn’t the only physical therapy provider in Marrickville, NSW, its name stands out from its competitors by providing highly effective and personalized services. The specialists offer services for patients of all ages and fitness levels and create a tailor-made plan with various options such as exercise physiology, Pilates exercise 101 and therapeutic massage. This practice is preferred by many athletes and people of all ages in general as it provides world class solutions to different needs.

Contact information

Movement 101 is located at Shop 2/198 Marrickville Rd, Marrickville, NSW 2204. If you have any questions about their Marrickville physical therapist, call the office on 02 9518 1585. For more information about their services or to book an appointment, visit Clinic website.

Media contact

Company Name
Movement 101
Contact name
Marcio
phone
02 9518 1585
Address
Shop 2/198 Marrickville Road
city
Marrickville
state
NSW
country
Australia
website
https://www.movement101.com.au/marrickville

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq® (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1≥1%. Data from the IMpower010 trial were published simultaneously in The Lancet. In IMpower010, treatment with Tecentriq, following surgery and chemotherapy, reduced the risk of disease recurrence or death (DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA NSCLC whose tumors express PD-L1≥1%, compared with best supportive care (BSC). Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.

“Today more than half of all people with early-stage NSCLC experience recurrence following surgery,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “IMpower010 shows how, for the first time, a cancer immunotherapy may help many of these patients live longer without their disease returning. The data presented at ESMO and WCLC further contribute to our understanding of Tecentriq in this treatment setting.”

At the 2021 ESMO Virtual Congress, new real-world data show that almost three-quarters of patients with early-stage NSCLC in the U.S. did not receive adjuvant treatment, despite guideline recommendations. Data presented from IMpower010 show that adjuvant Tecentriq offers a DFS benefit in the Stage II-IIIA patient population, irrespective of the stage of disease and across the main prior therapies. Specifically, time to relapse appeared to be improved with Tecentriq, compared with BSC, among people with Stage II-IIIA NSCLC whose tumors express PD-L1 TC ≥1%, for both locoregional and distant sites. There was no clear difference in patterns of relapse. An extended analysis of PD-L1 subgroups in the Stage II-IIIA population shows there is a higher magnitude of benefit from adjuvant Tecentriq in people with PD-L1 expression ≥50%, compared with those with 1-49% PD-L1 expression. The exploratory nature of the analysis in patients with 1-49% PD-L1 expression prevents any firm conclusions, and these data will be further analyzed and shared at a future medical congress.

Additional IMpower010 data, recently presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) Presidential Symposium, showed that treatment with Tecentriq improved DFS in the PD-L1≥1% Stage II-IIIA NSCLC population, compared with BSC, regardless of most surgery types and adjuvant chemotherapy regimens.

Based on the IMpower010 data, the U.S. Food and Drug Administration (FDA) recently granted Priority Review to Tecentriq as an adjuvant treatment for certain people with early NSCLC and is reviewing the application under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. The FDA is expected to make a decision on approval by December 1, 2021.

Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in markets around the world. It was the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy). Tecentriq also has four approved indications in advanced NSCLC as either a single agent or in combination with targeted therapies and/or chemotherapies. Tecentriq is available in three dosing options, providing the flexibility to choose administration every two, three or four weeks.

Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across different settings in lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant and neoadjuvant settings across various tumor types.

About the IMpower010 study

IMpower010 is a Phase III, global, multicenter, open-label, randomized study evaluating the efficacy and safety of Tecentriq compared with BSC, in participants with Stage IB-IIIA NSCLC (UICC 7th edition), following surgical resection and up to 4 cycles of adjuvant cisplatin-based chemotherapy. The study randomized 1,005 people with a ratio of 1:1 to receive either Tecentriq (up to 16 cycles) or BSC. The primary endpoint is investigator-determined DFS in the PD-L1-positive Stage II-IIIA, all randomized Stage II-IIIA and intent-to-treat (ITT) Stage IB-IIIA populations. Key secondary endpoints include overall survival (OS) in the overall study population, ITT Stage IB-IIIA NSCLC.

About lung cancer

According to the American Cancer Society, it is estimated that more than 235,000 Americans will be diagnosed with lung cancer in 2021, and NSCLC accounts for 80-85% of all lung cancers. Today, about half of all people with early lung cancer still experience a cancer recurrence following surgery, but treating lung cancer early, before it has spread, may help prevent the disease from returning and provide people with the best opportunity for a cure.

About Tecentriq® (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Tecentriq U.S. Indications

Tecentriq is a prescription medicine used to treat adults with:

A type of lung cancer called non-small cell lung cancer (NSCLC).

• Tecentriq may be used alone as their first treatment when their lung cancer:
  • has spread or grown, and
  • their cancer tests positive for “high PD-L1”, and
  • their tumor does not have an abnormal “EGFR” or “ALK” gene
• Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as their first treatment when their lung cancer:
  • has spread or grown, and
  • is a type called “non-squamous NSCLC,” and
  • their tumor does not have an abnormal “EGFR” or “ALK” gene
• Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as their first treatment when their lung cancer:
  • has spread or grown, and
  • is a type called “non-squamous NSCLC,” and
  • their tumor does not have an abnormal “EGFR” or “ALK” gene
• Tecentriq may also be used when their lung cancer:
  • has spread or grown, and
  • they have tried chemotherapy that contains platinum, and it did not work or is no longer working
  • if their tumor has an abnormal “EGFR” or “ALK” gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working

A type of lung cancer called small cell lung cancer (SCLC).

• Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as their first treatment when their lung cancer:
  • is a type called “extensive-stage small cell lung cancer,” which means that it has spread or grown

It is not known if Tecentriq is safe and effective in children.

Important Safety Information

What is the most important information about Tecentriq?

Tecentriq can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become severe or life threatening and can lead to death. Patients can have more than one of these problems at the same time. These problems may happen anytime during their treatment or even after their treatment has ended.

Patients should call or see their healthcare provider right away if they develop any new or worse signs or symptoms, including:

Lung problems

• cough
• shortness of breath
• chest pain

Intestinal problems

• diarrhea (loose stools) or more frequent bowel movements than usual
• stools that are black, tarry, sticky, or have blood or mucus
• severe stomach-area (abdomen) pain or tenderness

Liver problems

• yellowing of the skin or the whites of the eyes
• severe nausea or vomiting
• pain on the right side of their stomach area (abdomen)
• dark urine (tea colored)
• bleeding or bruising more easily than normal

Hormone gland problems

• headaches that will not go away or unusual headaches
• eye sensitivity to light
• eye problems
• rapid heartbeat
• increased sweating
• extreme tiredness
• weight gain or weight loss
• feeling more hungry or thirsty than usual
• urinating more often than usual
• hair loss
• feeling cold
• constipation
• their voice gets deeper
• dizziness or fainting
• changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

• decrease in their amount of urine
• blood in their urine
• swelling of their ankles
• loss of appetite

Skin problems

• rash
• itching
• skin blistering or peeling
• painful sores or ulcers in mouth or nose, throat, or genital area
• fever or flu-like symptoms
• swollen lymph nodes

Problems can also happen in other organs.

These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq. Patients should call or see their healthcare provider right away for any new or worse signs or symptoms, including:

• Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
• Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
• Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
• Persistent or severe muscle pain or weakness, muscle cramps
• Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

• chills or shaking
• itching or rash
• flushing
• shortness of breath or wheezing
• dizziness
• feeling like passing out
• fever
• back or neck pain

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if patients undergo transplantation either before or after being treated with Tecentriq. A healthcare provider will monitor for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider will check patients for these problems during their treatment with Tecentriq. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may also need to delay or completely stop treatment with Tecentriq if patients have severe side effects.

Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:

• have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
• have received an organ transplant
• have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
• have received radiation treatment to their chest area
• have a condition that affects their nervous system, such as myasthenia gravis or Guillain-Barré syndrome
• are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant:
  • A healthcare provider should do a pregnancy test before they start treatment with Tecentriq
  • They should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq
• are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into the breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

• feeling tired or weak
• nausea
• cough
• shortness of breath
• decreased appetite

The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:

• feeling tired or weak
• nausea
• hair loss
• constipation
• diarrhea
• decreased appetite

Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.

These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq.

Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Report side effects to Genentech at 1-888-835-2555.

Please see http://www.Tecentriq.com for full Prescribing Information and additional Important Safety Information.

About Genentech in cancer immunotherapy

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system.

In addition to Genentech’s approved PD-L1 checkpoint inhibitor, the company’s broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy.

About Genentech in lung cancer

Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.